Saturday, April 01, 2017 10:54:58 PM
chinatown1980,
If all SOC evented as per Dr. Linda Liau slide during presentation, how is that consistent with no treatment effect when 83 treatment patients had not yet evented? Secondly, GBM requires a slow acting immune response to prevent massive infiltration of immune cells leading to swelling and trauma to the brain. This has already been discussed ad nauseum. If you can't remember things very well then I suggest you write this down and repost this as a reminder before each and any of your future comments.
DC therapy combined with checkpoint inhibitors with reduced tumor burden after surgery or potentially at early detected recurrence, especially after an additional resection appears to have a strong to best possibility for positive benefit. This is why Dr. Prins would focus on combos for GBM even if some patients may not require them for positive benefit. The patient population able to gain maximum benefit from treatment increases with DC/checkpoint combos so focusing on combos, even if individual treatments find benefit to a lesser degree on their own, makes sense. I think you already know this but like I said, feel free to repost this as a header at the beginning of each of your future posts as a convenient reminder. Best wishes.
If all SOC evented as per Dr. Linda Liau slide during presentation, how is that consistent with no treatment effect when 83 treatment patients had not yet evented? Secondly, GBM requires a slow acting immune response to prevent massive infiltration of immune cells leading to swelling and trauma to the brain. This has already been discussed ad nauseum. If you can't remember things very well then I suggest you write this down and repost this as a reminder before each and any of your future comments.
DC therapy combined with checkpoint inhibitors with reduced tumor burden after surgery or potentially at early detected recurrence, especially after an additional resection appears to have a strong to best possibility for positive benefit. This is why Dr. Prins would focus on combos for GBM even if some patients may not require them for positive benefit. The patient population able to gain maximum benefit from treatment increases with DC/checkpoint combos so focusing on combos, even if individual treatments find benefit to a lesser degree on their own, makes sense. I think you already know this but like I said, feel free to repost this as a header at the beginning of each of your future posts as a convenient reminder. Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
